HIV-1 eradication: early trials (and tribulations)

AM Spivak, V Planelles - Trends in molecular medicine, 2016 - cell.com
Trends in molecular medicine, 2016cell.com
Antiretroviral therapy (ART) has rendered HIV-1 infection a manageable illness for those
with access to treatment. However, ART does not lead to viral eradication owing to the
persistence of replication-competent, unexpressed proviruses in long-lived cellular
reservoirs. The potential for long-term drug toxicities and the lack of access to ART for most
people living with HIV-1 infection have fueled scientific interest in understanding the nature
of this latent reservoir. Exploration of HIV-1 persistence at the cellular and molecular level in …
Antiretroviral therapy (ART) has rendered HIV-1 infection a manageable illness for those with access to treatment. However, ART does not lead to viral eradication owing to the persistence of replication-competent, unexpressed proviruses in long-lived cellular reservoirs. The potential for long-term drug toxicities and the lack of access to ART for most people living with HIV-1 infection have fueled scientific interest in understanding the nature of this latent reservoir. Exploration of HIV-1 persistence at the cellular and molecular level in resting memory CD4+ T cells, the predominant viral reservoir in patients on ART, has uncovered potential strategies to reverse latency. We review recent advances in pharmacologically based ‘shock and kill' HIV-1 eradication strategies, including comparative analysis of early clinical trials.
cell.com